Analysts Question Competitiveness Of Pfizer’s Monthly GLP-1 In Obesity

 
• By Joseph Haas
  
Pfizer's latest Phase IIb data in obesity look competitive, but not best in class (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business